Related references
Note: Only part of the references are listed.Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone
Ugo De Giorgi et al.
Oncotarget (2015)
Molecular Pathways: Targeting Resistance in the Androgen Receptor for Therapeutic Benefit
Elahe A. Mostaghel et al.
CLINICAL CANCER RESEARCH (2014)
Impact of Enzalutamide Administration on Primary Prostate Cancer Volume: A Metabolic Evaluation by Choline Positron Emission Tomography in Castration-Resistant Prostate Cancer Patients
Orazio Caffo et al.
CLINICAL GENITOURINARY CANCER (2014)
EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer
Axel Heidenreich et al.
EUROPEAN UROLOGY (2014)
11C-Choline PET/CT Predicts Prostate Cancer-Specific Survival in Patients with Biochemical Failure During Androgen-Deprivation Therapy
Giampiero Giovacchini et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
Prolonged exposure to (R)-bicalutamide generates a LNCaP subclone with alteration of mitochondrial genome
Sara Pignatta et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy REPLY
Tomasz M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis
X. Yuan et al.
ONCOGENE (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
T. M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Baseline 18F-FDG PET/CT Parameters as Imaging Biomarkers of Overall Survival in Castrate-Resistant Metastatic Prostate Cancer
Hossein Jadvar et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches
T. Karantanos et al.
ONCOGENE (2013)
Molecular Classification of Prostate Cancer Progression: Foundation for Marker-Driven Treatment of Prostate Cancer
Christopher J. Logothetis et al.
CANCER DISCOVERY (2013)
[C-11]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy
Maria Picchio et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2012)
Choline PET/CT compared with bone scintigraphy in the detection of bone metastases in prostate cancer patients
Mohsen Beheshti et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2012)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
18F-fluorocholine for prostate cancer imaging: a systematic review of the literature
G. Bauman et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2012)
New Strategies in Metastatic Prostate Cancer: Targeting the Androgen Receptor Signaling Pathway
Gerhardt Attard et al.
CLINICAL CANCER RESEARCH (2011)
Phase II Study of Abiraterone Acetate in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant with Serologic Response
Charles J. Ryan et al.
CLINICAL CANCER RESEARCH (2011)
F-18-Fluoromethylcholine (FCH) PET imaging in patients with castration-resistant prostate cancer: prospective comparison with standard imaging
Michael McCarthy et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2011)
Is there a role for C-11-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase < 1.5 ng/ml?
Paolo Castellucci et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2011)
Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer
U. De Giorgi et al.
ANNALS OF ONCOLOGY (2010)
Predictive factors of [11C]choline PET/CT in patients with biochemical failure after radical prostatectomy
Giampiero Giovacchini et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2010)
18F-FDG PET/CT Findings and Circulating Tumor Cell Counts in the Monitoring of Systemic Therapies for Bone Metastases from Breast Cancer
Ugo De Giorgi et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study
Howard I. Scher et al.
LANCET (2010)
The Use of F-18 Choline PET in the Assessment of Bone Metastases in Prostate Cancer: Correlation with Morphological Changes on CT
Mohsen Beheshti et al.
MOLECULAR IMAGING AND BIOLOGY (2010)
Dual Tracer 11C-Choline and FDG-PET in the Diagnosis of Biochemical Prostate Cancer Relapse After Radical Treatment
Jose A. Richter et al.
MOLECULAR IMAGING AND BIOLOGY (2010)
18F-choline PET/CT imaging of RECIST measurable lesions in hormone refractory prostate cancer
Sandi A. Kwee et al.
ANNALS OF NUCLEAR MEDICINE (2009)
Influence of Trigger PSA and PSA Kinetics on 11C-Choline PET/CT Detection Rate in Patients with Biochemical Relapse After Radical Prostatectomy
Paolo Castellucci et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Molecular imaging of prostate cancer with 18F-fluorodeoxyglucose PET
Hossein Jadvar
NATURE REVIEWS UROLOGY (2009)
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
The detection rate of [C-11]Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer
B. J. Krause et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2008)
Value of [11C]choline-positron emission tomography for re-staging prostate cancer:: A comparison with [18F]fluorodeoxyglucose-positron emission tomography
M Picchio et al.
JOURNAL OF UROLOGY (2003)
Comparison of [18F]fluorocholine and [18F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer
DT Price et al.
JOURNAL OF UROLOGY (2002)
Share Paper
